From Volume to Value: Healthcare Reform Reshapes Delivery Models and Diagnostic Laboratories

— Frost & Sullivan: Healthcare now geared toward tracking, predicting, intervening and managing disease conditions in a cost-effective manner

MOUNTAIN VIEW, Calif., Jan. 6, 2015 /PRNewswire/ — The in vitro diagnostics (IVD) industry and healthcare provider organizations are trying to function collaboratively to manifest a paradigm shift from routine disease management to prevention and wellness. Expectedly, enabling easy access to healthcare by offering advanced technologies at a lower cost is high on industry participants’ agenda.

Frost & Sullivan (

Frost & Sullivan (

Logo –

With the Affordable Care Act (ACA) bringing in a large number of new patients to the healthcare continuum, industry participants have to reevaluate their current business strategies. Clinical laboratories need to find alternative strategies to reduce the number of tests per patient as to avoid redundancy and save costs. In response, diagnostic laboratories will have to decrease costs and boost productivity to meet the expectation of lower reimbursement rates with increased testing volumes. Manufacturers too will have to support the labs with sophisticated technologies.

View the impacts of U.S. healthcare reform on the in vitro diagnostics market via Frost & Sullivan’s recent analysis:

"Healthcare reform is bringing in new delivery models such as accountable care organizations (ACOs); clinical laboratories will eventually blend in with ACOs to offer value-based healthcare," said Frost & Sullivan Life Sciences Senior Industry Analyst Divyaa Ravishankar. "In fact, new schemes on outcome-based reimbursement have already triggered interest in a move away from the traditional fee-for-service models. While laboratories might lose money as an entity by adopting the value-based healthcare system, overall welfare will increase, with better treatments for patients, and higher patient and physician satisfaction."

Electronic connectivity solutions will be the main tool to help eliminate unnecessary testing, provide seamless access to laboratory results throughout the continuum of care, improve the quality of testing, and reduce errors. Laboratories will opt for lean six sigma principles and connectivity solutions such as electronic medical records to access and upload test results from anywhere using the cloud and other applications. Clinical analytics will also become vital to bridge the existing gap between traditional laboratory testing and laboratory management (test utilization).

As such, the industry will see a rise in innovative partnership models among IVD manufacturers, diagnostic laboratories, software vendors and smartphone giants. Companies like Apple and Google are especially keen on rolling out disruptive technologies and supplemental modules for e-health.

"The market is ripe for IVD manufacturers that can invest to develop solutions that significantly lower turnaround times," noted Ravishankar. "Thus, integrating lab-on-a-chip with smartphones, revolutionizing point-of-care testing and decentralized testing, and introducing more patient self-testing products and devices are important for diagnostic test developers to taste success."

As patient self-testing and direct-to-consumer testing gains momentum, retail healthcare too will become a big business. Kroger has already taken a giant leap by installing pilot phase kiosks in its pharmacies and retail stores. Target has also been eyeing this market from the start of this year.

Frost & Sullivan has developed a highly successful IVD Market Intelligence Program to provide a comprehensive overview on the latest IVD market trends in global and emerging markets. IVD companies can leverage accurate and reliable market intelligence to develop goals and strategize. The studies offered include:

  • Analysis of the Global In Vitro Diagnostics Market
  • Impact of US Healthcare Reform on the In Vitro Diagnostics Market
  • US Hematology Diagnostics Market
  • Western European Companion Diagnostics Market
  • Analysis of the Global Tissue Diagnostics Market.

All the research deliverables are available in data packs (Excel format). The data tables will represent total installed base, revenue forecasts for different segments across selected geographies, market shares, and market trends for the forecast period.

For information or to be a part of our IVD Market Intelligence Program, please contact:

Jennifer Carson
Corporate Communications — North America
P: +

Twitter: @Frost_Sullivan

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation

Photo –

Leave a Reply